South Korea-based Lunit, a leading provider of AI for cancer diagnostics and precision oncology, has announced that US-based 10x Genomics, Inc. will incorporate Lunit’s AI-powered pathology platform, Lunit SCOPE IO, into its oncology biomarker discovery workflow.
Lunit SCOPE IO will be used to analyse Hematoxylin and Eosin (H&E) pathology images alongside spatial molecular data generated from 10x’s oncology-focused clinical research studies.
The work brings together molecular insights generated using 10x's Xenium and Atera spatial platforms with tissue characterization from Lunit SCOPE IO. By analszing pathology images alongside spatial molecular data, 10x aims to better understand how tissue morphology relates to the underlying biology of tumors and identify biomarkers associated with treatment response and resistance.
The work will initially support oncology clinical research studies focused on antibody-drug conjugates and immunotherapy response prediction. These studies are part of 10x’s broader effort to explore potential future diagnostic applications of spatial technologies in oncology.
Lunit SCOPE IO uses deep learning to analyse whole-slide H&E pathology images and characterise tissue features including tumor and stromal regions, immune-cell distribution, tertiary lymphoid structures and other features of the tumor microenvironment. Used alongside 10x's spatial technologies, these analyses provide additional tissue context that complements molecular profiling in oncology clinical research.
